S. 1414

Status: Reported

Expedited Access to Biosimilars Act

Expedited Access to Biosimilars Act

Sponsored by Rand Paul (Republican-KY)

Topics

Cosponsors

2

Actions

6

Roll calls

0

Amendments

0

Related bills

1

Actions

Jul 27, 2026 · Library of Congress

Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

Jul 27, 2026 · Senate

Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

Jul 27, 2026 · Senate

Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.

Jul 22, 2026 · Senate

Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

Apr 10, 2025 · Library of Congress

Introduced in Senate

Apr 10, 2025 · Senate

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest activity

July 2026

Bill reported · Jul 27Reported

Expedited Access to Biosimilars Act

Bill reported · Jul 27Reported

Expedited Access to Biosimilars Act

Lobbying reported · Whitmer & Worrall · Jul 22

Whitmer & Worrall reported 2nd Quarter (Apr 1 - June 30) lobbying for Campaign For Sustainable Drug Pricing (csrxp) — $50,000

BillsH.R. 1262 H.R. 1843 H.R. 3160 H.R. 3269 H.R. 3789 H.R. 4570 H.R. 5526 H.R. 6485 S. 43 S. 1032 S. 1040 S. 1041 S. 1096 S. 1414 S. 1546 S. 1954 S. 2658 S. 3014

Bill reported · Jul 22Reported

Expedited Access to Biosimilars Act

Lobbying reported · Biotechnology Innovation Organization · Jul 21

Biotechnology Innovation Organization reported 2nd Quarter (Apr 1 - June 30) lobbying for Biotechnology Innovation Organization — $2,360,000

Lobbying reported · Covington & Burling · Jul 20

Covington & Burling reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research Manufacturers Of America — $220,000

BillsH.R. 2715 H.R. 5526 H.R. 7953 H.R. 8646 S. 1414 S. 1954 S. 2658 S. 3014

Lobbying reported · America's Health Insurance Plans (ahip) · Jul 20

America's Health Insurance Plans (ahip) reported 2nd Quarter (Apr 1 - June 30) lobbying for America's Health Insurance Plans (ahip) — $3,010,000

BillsH.R. 1 H.R. 247 H.R. 379 H.R. 584 H.R. 608 H.R. 610 H.R. 842 H.R. 935 H.R. 950 H.R. 957 H.R. 1096 H.R. 1117 H.R. 1157 H.R. 1162 H.R. 1397 H.R. 1403 H.R. 1523 H.R. 1614 H.R. 1627 H.R. 1775 H.R. 1776 H.R. 1805 H.R. 1867 H.R. 1899 H.R. 1924 H.R. 2013 H.R. 2045 H.R. 2049 H.R. 2079 H.R. 2199 H.R. 2309 H.R. 2433 H.R. 2450 H.R. 2528 H.R. 2533 H.R. 2553 H.R. 2554 H.R. 2571 H.R. 2586 H.R. 2610 H.R. 2636 H.R. 2741 H.R. 3000 H.R. 3023 H.R. 3069 H.R. 3415 H.R. 3493 H.R. 3527 H.R. 3546 H.R. 3701 H.R. 3789 H.R. 3808 H.R. 4093 H.R. 4206 H.R. 4231 H.R. 4313 H.R. 4317 H.R. 4406 H.R. 4559 H.R. 4605 H.R. 4623 H.R. 4641 H.R. 4710 H.R. 5081 H.R. 5145 H.R. 5243 H.R. 5281 H.R. 5371 H.R. 5509 H.R. 5526 H.R. 5582 H.R. 5584 H.R. 6010 H.R. 6232 H.R. 6248 H.R. 6255 H.R. 6361 H.R. 6703 H.R. 6951 H.R. 6974 H.R. 7023 H.R. 7064 H.R. 7164 H.R. 7189 H.R. 7409 H.R. 7537 H.R. 7727 H.R. 7778 H.R. 7787 H.R. 7790 H.R. 7803 H.R. 7837 H.R. 7871 H.R. 8270 H.R. 8375 H.R. 8377 H.R. 8684 H.R. 8779 H.R. 8875 H.R. 9393 H.R. 9504 S. 339 S. 483 S. 526 S. 529 S. 652 S. 717 S. 729 S. 752 S. 864 S. 882 S. 891 S. 931 S. 939 S. 976 S. 1040 S. 1041 S. 1056 S. 1082 S. 1096 S. 1227 S. 1261 S. 1414 S. 1637 S. 1753 S. 1816 S. 1818 S. 1847 S. 1954 S. 1973 S. 2237 S. 2289 S. 2345 S. 2355 S. 2356 S. 2497 S. 2556 S. 2620 S. 2658 S. 2709 S. 2903 S. 3014 S. 3599 S. 3642 S. 3690 S. 3727 S. 3729 S. 3750 S. 3751 S. 3762 S. 3822 S. 3829 S. 3834 S. 3848 S. 3886 S. 3990 S. 4189 S. 4332 S. 4355 S. 4384 S. 4509 S. 4512

Lobbying reported · Pharmaceutical Care Management Association · Jul 20

Pharmaceutical Care Management Association reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Care Management Association — $3,282,990

Lobbying reported · Association for Accessible Medicines · Jul 20

Association for Accessible Medicines reported 2nd Quarter (Apr 1 - June 30) lobbying for Association for Accessible Medicines — $870,000

BillsH.R. 3160 H.R. 3269 H.R. 5526 H.R. 5811 H.R. 6485 H.R. 7148 H.R. 8269 H.R. 8339 S. 43 S. 1041 S. 1096 S. 1414 S. 1546 S. 1553 S. 1954 S. 2658 S. 3469 S. 3788

Lobbying reported · Kaiser Foundation Health Plan · Jul 20

Kaiser Foundation Health Plan reported 2nd Quarter (Apr 1 - June 30) lobbying for Kaiser Foundation Health Plan — $530,000

BillsH.R. 3269 H.R. 3514 H.R. 5429 H.R. 5526 H.R. 5582 H.R. 6248 H.R. 6644 H.R. 7148 H.R. 8800 H.R. 9393 H.R. 9504 S. 43 S. 1414 S. 1816 S. 1954 S. 2355 S. 2620 S. 2780 S. 3014 S. 3822 S. 4027 S. 4784

Lobbying reported · Fresenius Kabi USA · Jul 20

Fresenius Kabi USA reported 2nd Quarter (Apr 1 - June 30) lobbying for Fresenius Kabi USA — $580,000

BillsH.R. 3269 H.R. 5526 S. 1414 S. 1954 S. 2658

Lobbying reported · Amgen · Jul 20

Amgen reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $2,440,000

Lobbying reported · Pharmaceutical Research and Manufacturers of America (PhRMA) · Jul 20

Pharmaceutical Research and Manufacturers of America (PhRMA) reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $7,360,000

Lobbying reported · Fierce Government Relations · Jul 20

Fierce Government Relations reported 2nd Quarter (Apr 1 - June 30) lobbying for Association Of Accessible Medicines — $60,000

BillsH.R. 7410 S. 1414 S. 1954 S. 2658 S. 3014 S. 3788 S. 4327 S. 4784

Lobbying reported · Glaxosmithkline · Jul 16

Glaxosmithkline reported 2nd Quarter (Apr 1 - June 30) lobbying for Glaxosmithkline — $890,000

You’re all caught up.